Physician profile
Ashley Huggett
NPI 1073968491
$1,205.06
in general payments reported to CMS, 2019-2025
12 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $80.93 · 2023: $636 · 2024: $191 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.16 |
| Education | $279.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $353.49 | 2023-2025 | Cresemba |
| Abbvie INC. | $212.42 | 2022-2025 | |
| Viiv Healthcare Company | $141.75 | 2023-2025 | Dovato, Rukobia |
| Insmed, INC. | $125.00 | 2023 | Arikayce |
| Merck Sharp & Dohme LLC | $114.61 | 2022-2025 | Dificid, Pifeltro, Delstrigo |
| Gilead Sciences, INC. | $64.70 | 2023-2024 | Veklury, Epclusa |
| Melinta Therapeutics, LLC | $53.70 | 2022-2025 | Rezzayo, Vabomere |
| Shionogi INC | $51.87 | 2023-2024 | Fetroja |
| Paratek Pharmaceuticals, INC. | $29.02 | 2025 | Nuzyra |
| Theratechnologies INC. | $22.26 | 2022 | |
| Janssen Biotech, INC. | $18.81 | 2023 | Symtuza |
| La Jolla Pharmaceutical Company | $17.43 | 2023 | Xerava |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Huggett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.